The Oracle of Omaha has soured on these stocks, and perhaps you should, too.
These three scenarios could make claiming benefits early a smart choice.
Marijuana stocks are risky, but I think this company has what it takes to become a long-term winner.
These biotech upstarts have deep pockets and late-stage pipelines that could make them savvy buys.
Berkshire Hathaway's biggest buys in the third quarter include big banks and one Goliath technology stock (hint: It's not Apple).
Insurers and patients are increasingly embracing low-cost, on-demand healthcare solutions from companies like Teladoc.
Wall Street is growing increasingly concerned about the progress the company's making with a gene therapy for hemophilia A.
The company's sales are surging and a big jump in marijuana production next year suggests revenue could go even higher.
An insurer, a medical device company, and a healthcare Goliath could all be smart additions to portfolios this month.
Questions about its high-profile cardiovascular trial data are making investors more cautious.
Aurora Cannabis' sales are surging, and additional capacity and new products could drive revenue even higher next year.
Here's what you ought to know about Social Security next year.
A way to significantly increase your Social Security income.
This biotech is rethinking its priorities as it tries to successfully make the leap to a commercial-stage company.
Picking up shares in this research company, health insurer, and medical-device company could pay off for investors.
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
Early-stage results for a new approach to fighting cancer are sparking investors' optimism.
The attorney general's resignation could remove a big obstacle to changing how U.S. marijuana laws are enforced.
The company's making big strides toward winning approval of its first commercial medicine.
Michigan, Missouri, and Utah became the latest states to legalize marijuana on Nov. 6.